Do you routinely check EGFR mutational status in all resected NSCLC regardless of histology?

In the ADAURA trial, non-adenocarcinoma histology comprised < 5% of cases, which reflects the well-known distribution of sensitizing EGFR mutations which is largely found in adenocarcinomas. However, for patients who are never smokers or have remote light history of smoking with different NSCLC hist...